Cargando…

Cerebrospinal Fluid Levels of β-Amyloid 40 and β-Amyloid 42 are Proportionately Decreased in Amyloid Positron-Emission Tomography Negative Idiopathic Normal-Pressure Hydrocephalus Patients

BACKGROUND AND PURPOSE: Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) could be misleading in idiopathic normal-pressure hydrocephalus (iNPH). We therefore investigated the CSF biomarkers in 18F-florbetaben amyloid-negative positron-emission tomography (PET) [amyloid PET(−)] i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyun Jae, Lim, Tae Sung, Lee, Sun Min, Kim, Tae-Sung, Kim, Youngbin, An, Young-Sil, Youn, Young Chul, Park, Sun Ah, Chang, Jaerak, Moon, So Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Neurological Association 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620439/ https://www.ncbi.nlm.nih.gov/pubmed/31286708 http://dx.doi.org/10.3988/jcn.2019.15.3.353

Ejemplares similares

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
por: Motta, Caterina, et al.
Publicado: (2023)

Amyloid-β peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-β 42 aggregation
por: Braun, Gabriel A., et al.
Publicado: (2022)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017)

Cerebrospinal Fluid β-Amyloid(1–42) Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis
por: Mo, Jin-A, et al.
Publicado: (2015)

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
por: Wilczyńska, Karolina, et al.
Publicado: (2020)

High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis
por: Sturchio, Andrea, et al.
Publicado: (2021)

Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ(42)
por: An, Seong Soo A., et al.
Publicado: (2017)

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
por: Dumurgier, Julien, et al.
Publicado: (2015)

A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics
por: Al- Ayadhi, Laila Y, et al.
Publicado: (2012)

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity
por: Chun, Min Young, et al.
Publicado: (2023)

Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus
por: Kawamura, Kaito, et al.
Publicado: (2021)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity
por: Pyun, Jung-Min, et al.
Publicado: (2021)

The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort
por: Amft, Michaela, et al.
Publicado: (2022)

Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles
por: Liu, Huei-Chun, et al.
Publicado: (2020)

Amyloid β-peptides 1–40 and 1–42 form oligomers with mixed β-sheets
por: Baldassarre, Maurizio, et al.
Publicado: (2017)

Low cerebrospinal fluid Amyloid-βeta 1–42 in patients with tuberculous meningitis
por: Stroffolini, Giacomo, et al.
Publicado: (2021)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

Solid-phase synthesis and pathological evaluation of pyroglutamate amyloid-β(3-42) peptide
por: Cho, Illhwan, et al.
Publicado: (2023)

Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity
por: Sala, Arianna, et al.
Publicado: (2020)

Age-dependent inverse correlations in CSF and plasma amyloid-β(1–42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD mice
por: Cho, Soo Min, et al.
Publicado: (2016)

Microarray Analysis on Human Neuroblastoma Cells Exposed to Aluminum, β(1–42)-Amyloid or the β(1–42)-Amyloid Aluminum Complex
por: Gatta, Valentina, et al.
Publicado: (2011)

Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
por: Wisch, Julie K., et al.
Publicado: (2023)

Vascular Risk Predicts Plasma Amyloid β 42/40 Through Cerebral Amyloid Burden in Apolipoprotein E ε4 Carriers
por: Sapkota, Shraddha, et al.
Publicado: (2023)

Justicidin A Reduces β-Amyloid via Inhibiting Endocytosis of β-Amyloid Precursor Protein
por: Chun, Yoon Sun, et al.
Publicado: (2019)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Influence of denaturants on amyloid β42 aggregation kinetics
por: Weiffert, Tanja, et al.
Publicado: (2022)

secHsp70 as a tool to approach amyloid-β42 and other extracellular amyloids
por: De Mena, Lorena, et al.
Publicado: (2017)

Relationship of amyloid-β1–42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study
por: Lopez, Oscar L, et al.
Publicado: (2019)

Effect of apolipoprotein E phenotype on the association of plasma amyloid β and amyloid positron emission tomography imaging in Japan
por: Tateno, Amane, et al.
Publicado: (2017)

Effective screen for amyloid β aggregation inhibitor using amyloid β-conjugated gold nanoparticles
por: Han, Sun-Ho, et al.
Publicado: (2011)

Associative Interactions among Zinc, Apolipoprotein E, and Amyloid-β in the Amyloid Pathology
por: Oh, Shin Bi, et al.
Publicado: (2020)

Multifunctionalized Reduced Graphene Oxide Biosensors for Simultaneous Monitoring of Structural Changes in Amyloid-β 40
por: Jeong, Dahye, et al.
Publicado: (2018)

Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy
por: Yamashita, Kazuto, et al.
Publicado: (2022)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

X-ray diffraction and electron microscopy data for amyloid formation of Aβ40 and Aβ42
por: Selivanova, Olga M., et al.
Publicado: (2016)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Differentiating Aβ40 and Aβ42 in amyloid plaques with a small molecule fluorescence probe
por: Yang, Jing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r8uccp1734edj24afq0ts7h0sp